Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21- Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia

NCT02809092 is registered in ClinicalTrials.gov with Hospital de Clinicas de Porto Alegre as lead sponsor.

NCT NCT02809092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02809092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21- Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Hospital de Clinicas de Porto Alegre
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 1, 2017
Completion date
September 30, 2020
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia